From chemotherapy to targeted treatment

R. Dummer, S. Rozati, N. Eggmann, J. Rinderknecht, S. M. Goldinger

Research output: Contribution to journalArticlepeer-review

Abstract

Today, melanoma is considered as a spectrum of melanocytic malignancies that can be characterized by clinical and molecular features, including targetable mutations in several kinases. The successful development of therapies, targeting mutated BRaF (v-raf murine sarcoma viral oncogene homolog B1) or c-KIT (v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog), has resulted in new treatment options including vemurafenib, imatinib and mitogen-activated protein kinase inhibitors. These molecules are selected if the respective mutation is present. after this first progress in the treatment of advanced melanoma, there is expectation that combinations of kinase inhibitor will additionally improve the overall survival rates and progression-free survival in advanced melanoma.

Original languageEnglish (US)
Article numbermds308
Pages (from-to)x101-x103
JournalAnnals of Oncology
Volume23
Issue numberSUPPL. 10
DOIs
StatePublished - Sep 2012
Externally publishedYes

Keywords

  • Biochemotherapy
  • Chemotherapy
  • Kinase inhibitor
  • Melanoma
  • Metastatic melanoma
  • Targeted therapy

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'From chemotherapy to targeted treatment'. Together they form a unique fingerprint.

Cite this